Search This Blog

Tuesday, June 9, 2026

'Zelensky: Russia may be altering course of drones'

 Ukrainian President Volodymyr Zelensky claimed on Tuesday that Russia is altering the course of Ukrainian drones through electronic warfare systems, causing them to enter the airspace of neighboring countries.

In a post on X, Zelensky said that when drones appear in the skies over Latvia, Lithuania, or Estonia after Ukrainian strikes, "we understand that the Russians may be altering the course of our drones." He added that such incidents were caused by Russian electronic warfare systems and accused Moscow of seeking to escalate tensions within the European Union.

Zelensky said Ukraine and Estonia signed a joint declaration on security and defense cooperation, including air defense, defense industry cooperation, and the exchange of experience. He added that Kyiv is prepared to share expertise on countering drone threats with European partners and send expert teams under the "Drone Deal" format. Earlier, French President Emmanuel Macron stated that Russia is in a "situation of failure."

https://breakingthenews.net/Article/Zelensky:-Russia-may-be-altering-course-of-drones/66472559

Novanta to acquire Riverpoint Medical for $1.2B upfront plus $250M milestone

 

Novanta to acquire Riverpoint Medical for $1.2B upfront plus $250M milestone, accretive to adjusted EPS in 2026

  • Deal expected to close in the third quarter of 2026.

Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak

 Chinese biotech Zai Lab Limited (ZLAB) announced late Monday that Chinese regulators approved its antibody-drug conjugate Tivdak, developed with Pfizer (PFE) and Genmab (GMAB), as a late-line treatment for adults with cervical cancer.

Specifically, China’s National Medical Products Administration has cleared the Biologics License Application for Tivdak, targeted at adults with recurrent or metastatic cervical cancer who have previously undergone chemotherapy.

The decision is supported by data from a global Phase 3 trial called innovaTV 301, which indicated that the injectable led to a benefit in overall survival compared to chemotherapy in the targeted patient population, including a subset of Chinese patients.

An estimated 150K patients are diagnosed with cervical cancer in China each year, with those having the recurrent or metastatic forms of the disease having to deal with the cancer progression due to limited treatment options.

In 2022, Zai Lab (ZLAB) received exclusive licensing rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan as part of an agreement with Seagen, which Pfizer (PFE) acquired in 2023 for $43B.

https://www.msn.com/en-us/health/other/pfizer-zai-lab-win-china-nod-for-cervical-cancer-therapy-tivdak/ar-AA25bd6f

TG Therapeutics positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis

 

TG Therapeutics reports positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis

  • Company initiates potentially registration-directed Phase 2 maintenance trial of subcutaneous BRIUMVI in myasthenia gravis.
  • Phase 2 maintenance study follows efgartigimod induction therapy in patients with myasthenia gravis.

10x acquisition of Proteintech Genomics to expand single-cell and spatial proteomics

 

10x Genomics announces acquisition of Proteintech Genomics to expand single-cell and spatial proteomics capabilities

  • 10x Genomics says the deal will not meaningfully impact its near-term financial outlook
  • Proteintech Genomics is a Proteintech Group division focused on high-plex proteomic solutions for 10x platforms.

AMN Healthcare acquires AI-enabled medical interpretation provider Jaide Health

 

AMN Healthcare acquires AI-enabled medical interpretation provider Jaide Health to expand Language Services offerings

  • Jaide Health provides interpretation and translation services for limited English proficiency patients using AI-enabled technology; financial terms were undisclosed.

West Pharma upped to Overweight by Barclays

 Target $400

https://finviz.com/stock?t=WST&p=d